GLP-1s are developing too quickly to be contained within a weight-management strategy. They touch the assumptions beneath portfolio design, innovation, sensory optimization and category growth. The most useful response may begin not with a product concept, but with better questions.
The effects of GLP-1s become more consequential when we stop viewing them as a temporary route to weight loss and start considering the possibility of longer-term appetite management. The strategic question is not only how many people will use these medications, but how long their relationships with hunger, reward and impulse may remain altered.
Lilly’s oral GLP-1, orforglipron (now approved in the US as Foundayo) makes that possibility more tangible. In a dedicated maintenance trial, people switched directly from Wegovy or Zepbound to the once-daily pill and maintained significantly more of their previous weight loss than those who moved to placebo. Its significance therefore extends beyond convenience: it points towards a lower-friction future in which weight and appetite management could become a more routine, longer-term part of everyday life.
Many products benefit from frequency, habit and low-effort impulse. If those forces weaken, what remains? Brands need to identify the experiences that are genuinely worth choosing when hunger is lower and desire is quieter and distinguish them from products whose repeat purchase depends primarily on engineered craving.
Smaller appetites do not automatically mean smaller opportunities. They may shift value towards premium small bites, exceptional textures, multisensory ritual and highly intentional occasions. The commercial goal is not merely to defend quantity. It is to increase the meaning, usefulness and reward carried by every bite or sip.
Pleasure will not disappear, but its emotional payback may change. Consumers can still want comfort, celebration, discovery and escape without wanting excess. The next generation of indulgence may need to feel intense but bounded: more memorable, more reassuring and easier to stop.
Protein, fibre, hydration and portion control all matter. But they are ingredients in a response, not the response itself. A credible GLP-1 strategy must also account for fluctuating appetite, heightened sensory experiences, digestive tolerability, social eating and the emotional work of building a new identity around food.
The transition off medication can be psychologically and behaviorally fragile. Hunger and food noise may return before confidence and routines are ready. There is white space for brands that help people maintain structure, rebuild trust in their appetites and access pleasure without feeling that control has been lost.
The most important audience may not be a pharmaceutical cohort at all. As smaller portions, satiety, metabolic literacy and more intentional eating become visible, they can reset norms for everyone. The real disruption is not that one segment consumes differently. It is that the culture begins to value control over abundance.
The old growth model asked how brands could create more occasions. The GLP-1 era asks a harder question: how do you become worth choosing when ‘more’ is no longer the goal?
MMR combines evidence, experience and expertise to help brands turn the disruption of GLP‑1s into clearer decisions, stronger innovation and better product experiences. If you’re looking for a trusted global research partner for what comes next, let’s talk.